Epidermodysplasia verruciformis. Immunological and nonimmunological surveillance mechanisms: Role in tumor progression

Clinics in Dermatology

Volumn 15, Issue 3, 1997, Pages 321-334

  Majewski, Slawomir ^a   Jabłońska, Stefania ^a   Orth, Gérard ^a  

^a Klinika Dermatologiczna Medical University of Warsaw   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ALITRETINOIN; ALPHA INTERFERON; CALCITRIOL; CELL ADHESION MOLECULE; CYTOKINE; FLUOROURACIL; INTERFERON; INTERLEUKIN 12; ISOTRETINOIN; ONCOPROTEIN; RETINOIC ACID; RETINOID; SUNSCREEN;

ANIMAL TISSUE; CLINICAL FEATURE; DOSE RESPONSE; DRUG MIXTURE; EPIDERMODYSPLASIA VERRUCIFORMIS; HUMAN; HUMAN TISSUE; IMMUNE SYSTEM; INTRALESIONAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; PRECANCER; PRIORITY JOURNAL; REVIEW; SKIN CARCINOGENESIS; SKIN CARCINOMA; SKIN GRAFT; ULTRAVIOLET RADIATION; VIRUS CARCINOGENESIS; VIRUS GENE; WART VIRUS;

EID: 0343907170     PISSN: 0738081X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0738-081X(96)00169-1     Document Type: Article

References (122)

1. Orth G. Epidermodysplasia verruciformis: a model for understanding the oncogenicity of human papillomaviruses. Ciba Foundation Symposium 120, Papillomaviruses, Wiley, Chichester, 1986, pp 157-174.
2. Lewndowsky F, Lutz W. Ein Fall einer bisher nicht beschrieben: Hauterkrankung (Epidermodysplasia verruciformis). Arch Dermatol Syph (Berlin) 1922;141:193-203.
3. Orth G, Jablonska S, Favre M, et al. Characterization of two types of human papillomaviruses in lesions of epidermodysplasia verruciformis. Proc Natl Acad Sci USA 1978;75:1537-41.
4. Orth G, Jablonska S, Jarzabek-Chorzelska M, et al. Epidermodysplasia verruciformis: characteristic of the lesions and risk of malignant conversion as related to the type of human papillomavirus lesions. Cancer Res 1979; 39:1074-82.
5. Jablonska S, Dabrowski J, Jakubowicz K. Epidermodysplasia verruciformis as a model in studies on the role of papillomavirus in oncogenesis. Cancer Res 1972;32:585-9.
6. Shamanin V, Glover M, Rausch C, et al. Specific types of human papillomavirus found in benign proliferations and carcinomas of the skin in immunosuppressed patients. Cancer Res 1994;54:4610-3.
7. Berkhout RJ, Tieben LM, Smiths HI, et al. Nested PCR approach for detection and typing of epidermodysplasia verruciformis-associated human papillomavirus types in cutaneous cancers from renal transplant recipients. J Clin Microbiol 1995;33:690-5.
8. Tieben IM, Berkhout RJM, Smiths HL, et al. Detection of epidermodysplasia verruciformis-like human papillomavirus types in malignant and premalignant lesions of renal transplant recipients. Br J Dermatol 1994;131:226-30.
9. Shamanin V, zur Hausen H, Lavergne D, et al. HPV infections in non-melanoma skin cancers from renal transplant recipients and non-immunosuppressed patients. J Natl Cancer Inst (in press).
10. Jacyk WK, Subbuswanny SG. Epidermodysplasia verruciformis in Nigerians. Dermatologica 1979;159:256-65.
11. Jacyk WK, Dreyer L, de Villiers E-M. Seborrheic keratoses of black patients with epidermodysplasia verruciformis contain human papillomavirus DNA. Am J Dermatopath 1993;15:1-6.
12. Yutsudo M, Tanigaki T, Kanda R, et al. Involvement of human papillomavirus type 20 in epidermodysplasia verruciformis skin carcinogenesis. J Clin Microbiol 1994; 32:1076-8.
13. Lutzner MA, Orth G, Dutronquay V, et al. Detection of human papillomavirus type 5 DNA in skin cancers of an immunosuppressed renal allograft recipient. Lancet 1983;ii:422-4.
14. Pfister H, Iftner T, Fuchs PG. Papillomaviruses from epidermodysplasia verruciformis patients and renal allograft recipients. UCLA Symp Mol Cell Biol New Ser 1985;32:85-100.
15. Gross G, Ellinger K, Roussaki A, et al. Epidermodysplasia verruciformis in a patient with Hodgkins disease: characterization of a new papillomavirus type and interferon treatment. J Invest Dermatol 1988;91:43-8.
16. Barr BBB, Benton BC, McLaren K, et al. Human papilloma virus infection and skin cancer in renal allograft recipients. Lancet 1989;2:124-9.
17. Prose N, von Knebel-Doeberitz C, Miller S, et al. Widespread flat warts associated with human papillomavirus type 5: A cutaneous manifestation of human immunodeficiency virus infection. J Am Acad Dermatol 1990;23: 978-81.
18. Berger TG, Sawchuk WS, Leonardi C, et al. Epidermodysplasia verruciformis-associated with human immunodeficiency virus disease. Br J Dermatol 1991;124:79-83.
19. Van der Leest RJ, Dacjow KR, Ostrow RS, et al. Human papillomavirus heterogeneity in 36 renal transplant recipients. Arch Dermatol 1987;123:354-7.
20. Obalek S, Favre M, Szymanczyk J, et al. Human papillomavirus (HPV) types specific of epidermodysplasia verruciformis detected in warts induced by HPV 3 or HPV 3-related types in immunosuppressed patients. J Invest Dermatol 1992;98:936-41.
21. Lambert PF. Papillomavirus DNA replication. J Virol 1991;65:3417-20.
22. McGregor JM, Morris R, Smith C, et al. Skin cancer morbidity amongst renal allograft recipients. A 25 year retrospective follow-up study. Br J Dermatol 1995;133 (supplement 45):40.
23. Ferrándiz C, Fuente MJ, Ribera M, et al. Epidermal dysplasia and neoplasia in kidney transplant recipients. J Am Acad Dermatol 1995;33:590-96.
24. Proby CM, Shamanin IV, Rausch C, et al. Novel human papillomaviruses identified in skin cancers and keratinocyte cell lines from renal transplant recipients. Br J Dermatol 1995;132:644.
25. Bouwes Bavinck JN, Berkout RJM, Tieben LM, et al. DNA of EV-associated human papillomavirus in skin cancers from non-immunosuppressed patients. Abstract Book of the International Conference of Papillomavirus, Quebec 1995, p 93.
26. Bouwes Bavinck JN, Gissmann L, Claas FHJ, et al. Relation between skin cancer, humoral responses to human papillomaviruses, and HLA. Class-II molecules in renal transplant recipients. J Immunol 1993;151:1579-86.
27. Bouwes Bavinck JN, de Boer A, Vermeer BJ, et al. Sunlight, keratotic skin lesions and skin cancer in renal transplant recipients. Br J Dermatol 1993;129:242-9.
28. Bouwes Bavinck JN. Epidermodysplasia aspects of immunosuppression: role of exposure to sunlight and human papillomavirus on the development of skin cancer. Human and Exp Toxicol 1995;14:98.
29. Bouwes Bavinck JN, Tieben LM, van der Woude FJ, et al. Prevention of skin cancer and reduction of keratotic skin lesions during Acitretin therapy in renal transplant recipients. A double-blind placebo-controlled study. J Clin Oncol 1995;13:1933-8.
30. Lutzner M., Croissant O, Ducasse MF, et al. A potentially oncogenic human papillomavirus (HPV5) found in two renal allograft recipients. J Invest Dermatol 1980;75:353-6.
31. Soler C, Chardonnet Y, Euvrard S, et al. Evaluation of human papillomavirus type 5 on frozen sections of multiple lesions from transplant recipients with in situ hybridization and non isotopic probes. Dermatology 1992; 184:248-53.
32. zur Hausen H. Roots and perspectives of contemporary papillomavirus research. J Cancer Res Clin Oncol 1996; 122:3-13.
33. Majewski S, Breitburd F, Skopinska M, et al. A mouse model for studying epidermodysplasia verruciformis-associated carcinogenesis. Int J Cancer 1994;56:7727-30.
34. Adachi A, Kiyono T, Taguchi O, et al. Serial transplantation in SCID mice of an epidermodysplasia verruciformis-associated squamous cell carcinoma without alteration of its histological and virological features. Virology 1996;217:380-3.
35. Kiyono T, Nagashima K, Ishibashi M. The primary structure of major RNA in a rat cell line transfected with type 47 human papillomavirus DNA and the transforming activity of its cDNA and E6 gene. Virology 1989;173:551-5.
36. Kiyono T, Hiraiwa A, Ishibashi M. Differences in transforming activity and coded amino acid sequence among E6 genes of several papillomaviruses associated with epidermodysplasia verruciformis. Virology 1992;186: 628-634.
37. Yutsudo M, Hakura A. Human papillomavirus type 17 transcripts expressed in skin carcinoma tissue of a patient with epidermodysplasia verruciformis. Int J Cancer 1987;39:586-9.
38. Deau MC, Favre M, Orth G. Genetic heterogeneity among papillomaviruses (HPV) associated with epidermodysplasia verruciformis: Evidence for multiple allelic forms of HPV and HPV 8 E6 genes. Virology 1991;184: 492-503.
39. Iftner T, Sagner G, Pfister H, et al. The E7 protein of human papillomavirus 8 is a nonphosphorylated protein of 17 kDa and can be generated by two different mechanisms. Virology 1990;179:428-36.
40. Steger G, Pfister H. In vitro expressed HPV8 E6 protein does not bind p 53. Arch Virol 1992;125:355-9.
41. Iftner T, Bierfelder S, Csapo Z, et al. Involvement of human papillomavirus type 8 genes E6 and E7 in transformation and replication. J Virol 1988;62:3655-61.
42. Androphy EJ. Molecular biology of human papillomavirus infection and oncogenesis. J Invest Dermatol 1994; 103:248-56.
43. Kawase M, Orth G, Jablonska S, et al. Variability and phylogeny of the L1 capsid protein gene in human papillomavirus type 5: contribution of clusters of nonsynonymous mutations and a 30-nucleotide duplication. Virology 1996;221:189-98.
44. Brash DE, Rudolph JA, Simon JA, et al. A role of sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. Proc Natl Acad Sci USA 1991;88:10124-8.
45. Majewski S, Malejczyk J, Jablonska S, et al. Natural cell-mediated cytotoxicity against various target cells in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1990;22:423-7.
46. Cooper KD, Androphy EJ, Lowy DR, et al. Antigen presentation and T cell activation in epidermodysplasia verruciformis. J Invest Dermatol 1990;94:769-6.
47. Majewski S, Jablonska S. Epidermodysplasia verruciformis as a model of human papillomavirus-induced genetic cancers: the role of local immunosurveillance. Am J Med Sci 1992;304:174-9.
48. Majewski S, Skopinska-Rozewska E, Jablonska S, et al. Partial defects of cell-mediated immunity in patients with epidermodysplasia verruciformis. J Am Acad Dermatol 1986;15:966-73.
49. Kaminski M, Pawińska M, Jablonska S, et al. Increased natural killer cell activity in patients with epidermodysplasia verruciformis. Arch Dermatol 1985;121:84-6.
50. Tiggelar RE, Lewis JH. Immunobiology of mouse dendritic epidermal T cells: A decade later some answers, but still more questions. J Invest Dermatol 1995;105:43S-9S.
51. Born WK, Harshan K, Modlin RL, et al. The role of γδ T lymphocytes in infection. Curr Opin Immunol 1991;3: 455-9.
52. Modlin RL. Th1-Th2-paradigm: inaights from leprosy. J Invest Dermatol 1994;102:828-32.
53. Braciale TJ, Braciale VL. Antigen presentation: structural themes and functional variations. Immunol Today 1991; 12:124-9.
54. Braciale TJ. Antigen processing for presentation by MHC class I molecules. Curr Opin Immunol 1992;4:52-62.
55. Unanune ER. Cellular studies on antigen presentation by class II MHC molecules. Curr Opin Immunol 1992;4:63-9.
56. Karr RW, Yu W, Watts R, et al. The role of polymorphic HLA-DRB chain residues in presentation of viral antigens to T cells. J Exp Med 1990;172:273-83.
57. Monaco JJ. Genes in the MHC that may affect antigen processing. Curr Opin Immunol 1992;4:70-7.
58. Glynne R, Powis SH, Beck S, et al. A proteasome-related gene between the two ABC transporter loci in the class II region of the human MHC. Nature 1991;353:357-60.
59. Kelly A, Powis SH, Kerr L-A, et al. Assembly and function of the two ABC transporter proteins encoded in the human major histocompatibility complex. Nature 1992; 365:641-4.
60. Yoshikawa T, Streilein JW. Genetic basis of the effects of ultraviolet light B on cutaneous immunity. Evidence that polymorphism at the TNFα and Lps loci governs susceptibility. Immunogenetics 1990;32:398-405.
61. Han R, Breitburd F, Marche PN, et al. Linkage of regression and malignant conversion of rabbit viral papillomas to MHC class II genes. Nature 1992;356:66-8.
62. Han R, Breitburd F, Marche PN, et al. Analysis of the nucleolide sequence variation of the antigen-binding domain of DRα and DQα molecules as related to the evaluation of papillomavirus-induced warts in rabbits. J Invest Dermatol 1994;103:376-80.
63. Wank R, Thomssen C. High risk of squamous cell carcinoma of the cervix for women with HLA-DQw3. Nature 1991;352:723-5.
64. Apple JR, Erlich HA, Klitz W, et al. HLA DR-DQ associations with cervical carcinoma show papillomavirus-type specificity. Nature Genet 1994;6:157-67.
65. Bonagura VR, O'Reilly ME, Abramson AL, et al. Recurrent respiratory papillomatosis (RRP): enriched HLA DQw3 phenotype and decreased class I MHC expression. In: Steinberg BM, editor. Immunology of papillomaviruses. London: Plenum Press, 1993.
66. Favre M, Ramoz N, Jablonska S, et al. Search for a gene predisposing to epidermodysplasia verruciformis within the major histocompatibility complex. In: 14th International Papillomavirus Conference, Quebec, 1996 Book of Abstracts, p. 198.
67. Glinski W, Obalek S, Jablonska S, et al. T cell defect in patients with epidermodysplasia verruciformis due to human papillomavirus type 3 and 5. Dermatologica 1981;162:141-7.
68. Jablonska S, Majewski S. Epidermodysplasia verruciformis: Immunological and clinical aspects. Curr Topics Microbiol Immunol 1994;186:157-75.
69. Nishigori C, Yarosh DB, Donawho C, et al. The immune system in ultraviolet carcinogenesis. J Invest Dermatol Symp Proc 1996;1:143-6.
70. Haftek M, Jablonska S, Szymanczyk J, et al. Langerhans cells in epidermodysplasia verruciformis. Dermatologica 1987;174:173-9.
71. Simon JC, Cruz PD, Bengstresser PR, et al. Low-dose UVB-irradiated Langerhans cells preferentially activate CD4 cells of the Th1 subset. J Immunol 1990;145:2087-91.
72. Krutmann J, Bohnert E, Jung EG. Evidence that DNA damage is a mediate in ultraviolet B radiation-induced inhibition of human gene expression: ultraviolet B radiation effects on intercellular adhesion molecule-1 expression. J Invest Dermatol 1994;102:428-32.
73. Nickoloff B, Turka LA, Mitra RS, et al. Direct and indirect control of T cell activation by keratinocytes. J Invest Dermatol 1995;95:111S-7S.
74. Ding L, Linsley PS, Huang LY, et al. IL-10 inhibits macrophage costimulatory activity by selectively inhibiting the up-regulation of B7 expression. J Immunol 1993;151: 1224-34.
75. Majewski S, Hunzelmann N, Nischt R, et al. TGFB-1 and TNF expression in the epidermis of patients with epidermodysplasia verruciformis. J Invest Dermatol 1991;97: 862-7.
76. Streilein JW. Sunlight and skin-associated lymphoid tissues (SALT): If UVB is the trigger and TNFα is its mediator, what is the message? J Invest Dermatol 1993;100: 47S-52S.
77. Ross JA, Howie SEM, Norval M, et al. Ultraviolet-irradiated urocanic acid suppresses delayed-type hypersensitivity to herpes simplex virus in mice. J Invest Dermatol 1986;87:630-3.
78. Harriot-Smith. TG, Halliday WJ. Suppression of contact hypersensitivity by short-term ultraviolet irradiation. The role of urocanic acid. Clin Exp Immunol 1988;72: 174-9.
79. Roberts AB, Sporn MB. The transforming growth factor-beta In: Sporn MB, Roberts AB, editors. Handbook of experimental pharmacology. Berlin: Springer 1990:419-72.
80. Wahl SM, Hunt DA, Wakefield LM, et al. Transforming growth factor type induces monocyte chemotaxis and growth factor production. Proc Natl Acad Sci USA 1987; 84:5788-92.
81. Rivas JH, Ullrich SE. Systemic suppression of delayed-type hypersensitivity by supernatants from UV-irradiated keratinocytes an essential role for keratinocyte-derived IL-10. J Immunol 1992;149:3865-71.
82. Sieling PA, Abrams JS, Yamamura M, et al. Immunosuppressive roles for IL-10 and in human infection. J Immunol 1993;150:5501-6.
83. Schwarz A, Grabbe S, Rieman H, et al. In vivo effects of interleukin-10 on contact hypersensitivity and delayed-type hypersensitivity reactions. J Invest Dermatol 1994; 103:211-6.
84. Bhardwaj RS, Luger TA. Proopiomelanocortin production by epidermal cells: evidence for an immune neuro-endocrine network in the epidermis. Arch Dermatol Res 1994;287:85-90.
85. Wintzen M, Gilchrest BA. Proopiomelanocortin, its derived peptides, and the skin. J Invest Dermatol 1996;106: 3-10.
86. Jablonska S. Epidermodysplasia verruciformis. In: RJ Friedman et al., editors. Cancer of the skin. Philadelphia: WB Saunders, 1991:101-13.
87. Chakraborty A, Slominski A, Ermark G, et al. Ultraviolet B and melanocyte-stimulating hormone (MSH) stimulate mRNA production for aMSH receptors and proopiomelanocortin-derived peptides in mouse melanoma cells and transformed keratinocytes. J Invest Dermatol 1995;105:655-9.
88. Cannon JG, Tatro JB, Reichlin S, et al. a-Melanocyte-stimulating hormone inhibits immunostimulatory and inflammatory action of interleukin 1. J Immunol 1986; 137:2232-8.
89. Hiltz ME, Catania EA, Lipton JM. a-MSH peptides inhibit acute inflammation induced in mice by rIL-1beta, rIL-6, rTNFa and endogeneous pyrogen but not that caused by LTB4, PAF and rIL-Cytokine 1992;4:320-8.
90. Bhardwaj RS, Arange Y, Becher E, et al. Alpha melanocyte stimulating hormone differentially regulates IL-10 by human peripheral blood mononuclear cells. J Invest Dermatol 1994;102:586-90.
91. Grabbe S, Bhardwaj RS, Mahnke K, et al. a-Melanocyte-stimulating hormone induces hapten-specific tolerance in mice. J Immunol 1996;156:473-8.
92. Comerci JT, Runowicz CD, Flanders KC, et al. Altered expression of transforming growth factor-b1 in cervical neoplasia as an early biomarker in carcinogenesis of the uterine cervix. Cancer 1996;77:1107-14.
93. Glick AB, Kulkarni AB, Tennenbaum T, et al. Loss of expression of transforming growth factor beta in skin and skin tumors is associated with hyperproliferation and a high risk for malignant conversion. Proc Natl Acad Sci USA 1993;90:6076-80.
94. Glick AB, Lee MM, Darwiche N, et al. Targeted depletion of the TGF-b1 gene causes rapid progression to squamous cell carcinoma. Genes Dev 1994;8:2429-40.
95. Pepper MS, Belin D, Montesano R, et al. Transforming growth factor-beta 1 modulates basic fibroblast growth factor-induced proteolytic and angiogenic properties of endothelial cell in vitro. J Cell Biol 1990;111:743-55.
96. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1954; 79:315-28.
97. Hynes RO. Integrins: versatility, modulation, and signaling in cell adhesion. Cell 1992;69:11-7.
98. Peltonen J, Larjava H, Jaakkola S, et al. Localization of integrin receptors for fibronectin, collagen and laminin in human skin. Variable expression in basal and squamous cell carcinomas. J Clin Invest 1989;84:1916-23.
99. Cerri A, Tadini G, Gotto R, et al. Adhesion molecules and skin tumors: a peculiar pattern of integrin expression is present in carcinoma cells. Eur J Dermatol 1992;2:279-85.
100. Demeter LM, Stoler MH, Sobel MF, et al. Expression of high-affinity laminin receptor mRNA correlates with cell proliferation rather than invasion in human papillomvirus-associated cervical neoplasia. Cancer Res 1992;52: 1561-8.
101. Androphy EJ, Dvoretzky I, Malnish AE. Response of warts in epidermodysplasia verruciformis to treatment with systemic oral and intralesional alpha interferon. J Am Acad Dermatol 1984;11:197-202.
102. Jablonska S, Orth G, Obalek S, et al. 21 years of follow up of familial epidermodysplasia verruciformis. Dermatologica 1979;158:309-27.
103. Jablonska S, Obalek S, Orth G, et al. Regression of the lesions of epidermodysplasia verruciformis. Br J Dermatol 1982;107:109-16.
104. Jablonska S, Orth G. Epidermodysplasia verruciformis. Clin Dermatol 1985;3:83-96.
105. zur Hausen H. Genital papillomavirus infections. In: Rigby PWJ, Wilkie NM, editors. Viruses and Cancer, Society for General Microbiology Symposium 37. Cambridge: Cambridge University Press, 1985:83-90.
106. Shroyer KR, Brookes CG, Markham NE, et al. Detection of human papillomavirus in anorectal squamous cell carcinoma: correlation with basaloid pattern of differentiation. Am J Clin Pathol 1995;104:299-305.
107. Jablonska S, Biczysko W, Jakubowicz K, et al. The ultra-structure transitional status of Bowen's disease and invasive Bowen's carcinoma in epidermodysplasia verruciformis. Dermatologica 1970;140:186-94.
108. Kuligowski M, Dabrowski JH, Jablonska S. Apoptosis in Bowen's disease. An ultrastructural study. Am J Dermatopathol 1989;11:13-21.
109. Majewski S, Marczak M, Jablonska S. Effects of retinoids on angiogenesis and on the proliferation of endothelial cells in vitro. In: Reichert U, Shroot B, editors. Pharmacology of retinoids in the skin, vol. 3. Basel: Karger 1989: 94-5.
110. Lotan R, Lotan D, Sacks PG. Inhibition of tumor cell growth by retinoids. Methods Enzymol 1990;190:100-10.
111. Rudnicka L, Marczak M, Szmurlo A, et al. Acitretin decreases tumor cell-induced angiogenesis. Skin Pharmacol 1991;4:150-3.
112. Majewski S, Szmurlo A, Marczak M, et al. Synergistic effect of retinoids and interferon alpha on tumor-induced angiogenesis: Anti-angiogenic effect on HPV-harboring tumor-cell lines. Int J Cancer 1994;57:81-5.
113. Sacks PG, Harris D, Chou TC. Modulation of growth and proliferation in squamous cell carcinoma by retinoic acid: a rationale for combination therapy with chemotherapeutic agents. Int J Cancer 1995;61:409-15.
114. Lingen MW, Polverini PJ, Bouck NP. Retinoic acid induces cells cultured from rat squamous cell carcinomas to become anti-angiogenic. Am J Pathol 1996;149:247-58.
115. Jablonska S, Obalek S, Wolska H, et al. Ro-10-9359 in epidermodysplasia verruciformis. Preliminary raport. In: CE, et al., editors, retinoids. Orfanos Berlin: Springer-Verlag, 1981:401-5.
116. Blanchet-Bardon C, Lutzner MA. Interferon and retinoids in the therapy of HPV-induced lesions. Clin Dermatol 1985;3:195-9.
117. Majewski S, Szmurlo A, Marczak M, et al. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Lett 1993;75:35-9.
118. Majewski S, Marczak M, Szmurlo A, et al. Retinoids combined with interferon alpha or 1,25-dihydroxy-vitamin D3 synergistically inhibit angiogenesis induced by non-HPV harboring tumor cell lines. Cancer Lett 1995;89:117-24.
119. Majewski S, Skopinska M, Bollag W, et al. Combination of isotretinoin and calcitriol for precancerous and cancerous skin lesions. Lancet 1994;344:1510-1.
120. Skopińska M, Majewski S, Bollag W, et al. Calcitrol and isotretinoin: combined therapy for precancerous and cancerous skin lesions. J Dermatol Treat 1996 (in press).
121. Schwarz A, Grabbe S, Aragane Y, et al. Interleukin-12 provents ultraviolet β-induced local immunosuppression and overcomes UVB-induced tolerance. J Invest Dermatol 1996;106:1187-91.
122. Majewski S, Marczak M, Szmurlo A, et al. Interleukin-12 inhibits angiogenesis induced by human tumor cell lines in vivo. J Invest Dermatol 1996;106:1114-8.